Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer

NCT00379015 is registered in ClinicalTrials.gov with Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan as lead sponsor.

NCT NCT00379015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00379015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
March 31, 2016
Enrollment
38 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer